A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) (NCT06644781)

🧪 Interventions in This Study

• Ifinatamab deruxtecan (DRUG)
• Docetaxel (DRUG)
• Paclitaxel (DRUG)
• Irinotecan hydrochloride (HCl) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (132 Sites)

Showing the first 25 of 132 sites.

• Mayo Clinic Hospital — Phoenix, Arizona
• Providence Medical Foundation — Fullerton, California
• Univ of California Irvine College of Medicine — Orange, California
• Henry Ford Health System — Detroit, Michigan
• Mayo Clinic Rochester — Rochester, Minnesota
• MidAmerica Cancer Care - American Oncology Partners — Kansas City, Missouri
• Morristown Medical Center — Morristown, New Jersey
• Maimonides Cancer Center — Brooklyn, New York
• Penn State University Milton S. Hershey Medical Center — Hershey, Pennsylvania
• Baptist Cancer Center — Memphis, Tennessee
• SCRI Oncology Partners — Nashville, Tennessee
• John Peter Smith Hospital — Fort Worth, Texas
• Virginia Cancer Specialists — Fairfax, Virginia
• Institut Jules Bordet — Brussels,
• Cliniques Universitaires Saint-Luc — Brussels,
• Antwerp University Hospital — Edegem,
• UZ Leuven — Leuven,
• Chu de Liege — Liège,
• Anyang Cancer Hospital — Anyang,
• Beijing Cancer Hospital — Beijing,
• Jilin Cancer Hospital — Changchun,
• Changzhou Cancer Hospital — Changzhou,
• Sichuan cancer hospital — Chengdu,
• West China Hospital Sichuan University — Chengdu,
• Fujian Cancer Hospital — Fuzhou,

📞 Contact the Study Coordinator

Phone: (908) 992-6400

Email: CTRinfo_us@daiichisankyo.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Esophageal Squamous Cell Carcinoma

• A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy — Fort Myers, Florida
• Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC — Atlanta, Georgia
• Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) — Pittsburgh, Pennsylvania
• A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) — Tucson, Arizona
• Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer — Montreal, Quebec
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types — Denver, Colorado

Explore by condition: All Esophageal Squamous Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.